The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a single ...
A stroke is often thought of as a condition of adulthood, yet it remains a significant and underrecognized cause of morbidity and mortality in the pediatric population. Despite being cited among the ...
Over nearly the last three decades, Genentech has had the lone medicine on the market for the acute treatment of stroke. Monday, the Roche subsidiary added a second stroke treatment to its repertoire, ...
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results